A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Condition:   Atopic Dermatitis Interventions:   Drug: 1.5% QLM3003;   Drug: 2% QLM3003;   Drug: Vehicle (Placebo) Sponsor:   Qilu Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials